CDK16 and cancer: Moreover, CDK16 inhibition downregulated MYC and PD‐L1 in NSCLC cells, suggesting that the enhanced antitumor immune response may be a downstream effect of inducing cancer cell senescence to exercise its tumor‐suppressive function.